Products for Research Use Only
RegisterLogin

HX531

CAT: 0804-HY-108521-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-108521-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities[1][2][3].
CAS Number
188844-34-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; MDM-2/p53; RAR/RXR
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/hx531.html
Purity
99.87
Solubility
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(O)C1=CC=C(C2=NC3=CC([N+]([O-])=O)=CC=C3N(C)C4=CC5=C(C(C)(C)CCC5(C)C)C=C42)C=C1
Molecular Formula
C29H29N3O4
Molecular Weight
483.56
Precautions
H302, H315, H319, H335
References & Citations
[1]Konta T, et al. Selective roles of retinoic acid receptor and retinoid x receptor in the suppression of apoptosis by all-trans-retinoic acid. J Biol Chem. 2001 Apr 20;276 (16) :12697-701. |[2]Yamauchi T, et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest. 2001 Oct;108 (7) :1001-13.|[3]Atsuko Nakatsuka, et al. RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21 (Cip1) pathway in adipocytes. J Pathol. 2012 Apr;226 (5) :784-95.|[4]Wenrui Zhao, et al. RXR signaling targeted cancer therapy. January 2023The Innovation Life 1 (1) :100014
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
E1767-100mgHX531

Popular Products